MTOR and renal cell carcinoma: In cancers with mTOR gain-of-function mutations, such as glioblastoma or renal cell carcinoma [103], CRISPR-Cas9 can be used to selectively knock out the mutated allele, thereby reducing excessive mTOR signaling, which could help control tumor growth driven by mTOR overactivation.